| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1359-6101(00)00030-7 |
| P698 | PubMed publication ID | 11312114 |
| P2093 | author name string | Wilson K | |
| Horowitz MC | |||
| Xi Y | |||
| Kacena MA | |||
| P2860 | cites work | The receptor for the cytotoxic ligand TRAIL | Q24310481 |
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 | ||
| Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells | Q24321566 | ||
| Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis | Q24324701 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif | Q28138697 | ||
| Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice | Q28140546 | ||
| Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis | Q28141482 | ||
| Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival | Q28142897 | ||
| Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex | Q28145172 | ||
| Genetic linkage of familial expansile osteolysis to chromosome 18q | Q28237649 | ||
| Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation | Q28240596 | ||
| An antagonist decoy receptor and a death domain-containing receptor for TRAIL | Q28245153 | ||
| Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase | Q28278061 | ||
| The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor | Q28285539 | ||
| RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 | ||
| TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling | Q28513445 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death | Q28609905 | ||
| Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts | Q29547605 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Mesenchymal stem cells | Q29619804 | ||
| Characterization of structural domains of human osteoclastogenesis inhibitory factor | Q34457751 | ||
| Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro | Q34459310 | ||
| Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. | Q34469691 | ||
| Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection | Q35008871 | ||
| Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression | Q35169193 | ||
| Modulation of osteoclast differentiation | Q35957509 | ||
| Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE | Q36368551 | ||
| Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors | Q36375584 | ||
| Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene | Q37265676 | ||
| Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha | Q37271202 | ||
| Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells | Q38336153 | ||
| Cytokines and estrogen in bone: anti-osteoporotic effects | Q40900427 | ||
| Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis | Q40926683 | ||
| Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells | Q40927574 | ||
| Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines | Q41000781 | ||
| Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells | Q41004339 | ||
| Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells | Q41016610 | ||
| Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells | Q41016675 | ||
| TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption | Q41027241 | ||
| Regulation of osteoclast function | Q41486748 | ||
| Osteoblastic gene expression during adipogenesis in hematopoietic supporting murine bone marrow stromal cells | Q41575889 | ||
| Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation | Q42475736 | ||
| The cell-surface form of colony-stimulating factor-1 is regulated by osteotropic agents and supports formation of multinucleated osteoclast-like cells. | Q42831612 | ||
| Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse | Q43681246 | ||
| Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. | Q45946808 | ||
| cAMP stimulates osteoblast-like differentiation of calcifying vascular cells. Potential signaling pathway for vascular calcification. | Q45996887 | ||
| Osteoblastic cells are involved in osteoclast formation. | Q54374668 | ||
| Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene | Q58008649 | ||
| T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ | Q59064307 | ||
| The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene | Q59092154 | ||
| Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids | Q61480394 | ||
| The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells | Q69541163 | ||
| Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord | Q73766127 | ||
| Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast | Q77350563 | ||
| Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells | Q77484251 | ||
| Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF) | Q77630526 | ||
| Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells | Q77630549 | ||
| P433 | issue | 1 | |
| P921 | main subject | TNF | Q18032037 |
| P304 | page(s) | 9-18 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Cytokine and Growth Factor Reviews | Q15763303 |
| P1476 | title | Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands | |
| P478 | volume | 12 |
| Q90453763 | A diet containing high- versus low-daidzein does not affect bone density and osteogenic gene expression in the obese Zucker rat model |
| Q61797725 | ALVEOLAR BONE PATTERN AND SALIVARY LEPTIN LEVELS AMONG PREMENOPAUSAL OBESE WOMEN |
| Q42148836 | Adenoviral vector-mediated overexpression of osteoprotegerin accelerates osteointegration of titanium implants in ovariectomized rats |
| Q28730665 | Age-related skeletal dynamics and decrease in bone strength in DNA repair deficient male trichothiodystrophy mice |
| Q34130186 | Amelioration of rat adjuvant-induced arthritis by Met-RANTES. |
| Q36567407 | An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice |
| Q79361043 | Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells |
| Q33997446 | Bone status in patients with epilepsy: relationship to markers of bone remodeling |
| Q50069691 | C/EBPα and PU.1 exhibit different responses to RANK signaling for osteoclastogenesis |
| Q47419391 | C/EBPα is Regulated by the RANK Cytoplasmic IVVY535-538 Motif and Stimulates Osteoclastogenesis more Strongly than c-Fos |
| Q55070022 | CA-074Me compound inhibits osteoclastogenesis via suppression of the NFATc1 and c-FOS signaling pathways. |
| Q42175353 | CCAAT/Enhancer-binding Protein α (C/EBPα) Is Important for Osteoclast Differentiation and Activity |
| Q38193090 | Classical and Paradoxical Effects of TNF-α on Bone Homeostasis |
| Q28573446 | Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts |
| Q92451368 | Cyclic compression emerged dual effects on the osteogenic and osteoclastic status of LPS-induced inflammatory human periodontal ligament cells according to loading force |
| Q51220391 | Cyclical tensile force on periodontal ligament cells inhibits osteoclastogenesis through OPG induction. |
| Q60931719 | Determination of the optimal diabetes duration for bone regeneration experiments in an alloxan-induced diabetic rabbit calvarial defect model |
| Q52551676 | Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. |
| Q28704623 | Diabetes, biochemical markers of bone turnover, diabetes control, and bone |
| Q39842854 | Dietary quercetin inhibits bone loss without effect on the uterus in ovariectomized mice |
| Q74701407 | Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR |
| Q34642194 | Differentially expressed genes strongly correlated with femur strength in rats |
| Q35677638 | Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis |
| Q90456871 | Does idiopathic hypercalciuria affect bone metabolism during childhood? A prospective case-control study |
| Q79175559 | Does infliximab decrease bone turnover in rheumatoid arthritis patients |
| Q53929884 | Effect of soluble receptors to interleukin-1 and tumor necrosis factor alpha on experimentally induced root resorption in rats. |
| Q85161257 | Effects of HSP70 on the compression force-induced TNF-α and RANKL expression in human periodontal ligament cells |
| Q64891933 | Effects of RANKL, osteoprotegerin, calcium and phosphorus on survival and activation of Muscovy duck osteoclasts in vitro. |
| Q38972516 | Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts. |
| Q51208785 | Effects of yuja peel extract and its flavanones on osteopenia in ovariectomized rats and osteoblast differentiation. |
| Q34101059 | Emerging lung cancer therapeutic targets based on the pathogenesis of bone metastases |
| Q44395882 | Expression of connexin 43 mRNA in microisolated murine osteoclasts and regulation of bone resorption in vitro by gap junction inhibitors |
| Q82792762 | Expression of osteoprotegerin and receptor activator of nuclear factor κB ligand in root resorption induced by heavy force in rats |
| Q36956236 | Genomic expression analysis of rat chromosome 4 for skeletal traits at femoral neck |
| Q24813377 | Glucocorticoid receptor-dependent gene regulatory networks. |
| Q36065521 | Glucocorticoid-induced osteoporosis: from basic mechanisms to clinical aspects |
| Q36362686 | Host responses in maintaining periodontal health and determining periodontal disease |
| Q47880647 | Identification of RANKL in osteolytic lesions of the facial skeleton. |
| Q42499853 | Immunohistochemical expression of RANKL, RANK and OPG in gingival tissue of patients with periodontitis |
| Q24815939 | Immunolocalization of RANKL is increased and OPG decreased during dietary magnesium deficiency in the rat |
| Q28511232 | Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene |
| Q37842459 | Influences of bone and mineral metabolism in epilepsy. |
| Q37071670 | Inhibiting myostatin signaling prevents femoral trabecular bone loss and microarchitecture deterioration in diet-induced obese rats |
| Q34024780 | Is GSN significant for hip BMD in female Caucasians? |
| Q53815838 | Ladder-Climbing Training Prevents Bone Loss and Microarchitecture Deterioration in Diet-Induced Obese Rats. |
| Q24299233 | Leupaxin is a critical adaptor protein in the adhesion zone of the osteoclast |
| Q98944918 | Lipocalin-2 deficiency may predispose to the progression of spontaneous age-related adiposity in mice |
| Q52012973 | Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts. |
| Q39724201 | Long-term sequential receptor activator of NF-κB ligand (RANKL) and osteoprotegrin (OPG) expression in lipopolysaccharide-induced rat periapical lesions |
| Q52806621 | Loss of the hematopoietic stem cell factor GATA2 in the osteogenic lineage impairs trabecularization and mechanical strength of bone. |
| Q38640619 | Markers of bone turnover in patients with epilepsy and their relationship to management of bone diseases induced by antiepileptic drugs. |
| Q35024511 | Mediators of periodontal osseous destruction and remodeling: principles and implications for diagnosis and therapy |
| Q38837134 | Monosodium Urate in the Presence of RANKL Promotes Osteoclast Formation through Activation of c-Jun N-Terminal Kinase |
| Q59797072 | Nox2 Activity Is Required in Obesity-Mediated Alteration of Bone Remodeling |
| Q34388316 | Obesity-mediated inflammatory microenvironment stimulates osteoclastogenesis and bone loss in mice |
| Q37566020 | On a path to unfolding the biological mechanisms of orthodontic tooth movement |
| Q56638116 | Osteoclastogenesis during Infective Exacerbations in Patients with Cystic Fibrosis |
| Q46389765 | Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. |
| Q35150595 | Protective role of n-3 lipids and soy protein in osteoporosis |
| Q51426261 | RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro. |
| Q37694061 | RANK/RANKL/OPG role in distraction osteogenesis |
| Q43987138 | Raloxifene modulates regulators of osteoclastogenesis and angiogenesis in an oestrogen deficiency periapical lesion model |
| Q38884628 | Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling. |
| Q24633744 | Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin |
| Q54646116 | Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain. |
| Q28384638 | Role of TNF alpha and PLF in bone remodeling in a rat model of repetitive reaching and grasping |
| Q35078755 | Short-term and long-term orthopaedic issues in patients with fragility fractures |
| Q84514569 | Simvastatin attenuates TNF-alpha-induced growth inhibition and apoptosis in murine osteoblastic MC3T3-E1 cells |
| Q28261418 | Skeletal and hormonal effects of magnesium deficiency |
| Q36045625 | Streptococcus pyogenes infection induces septic arthritis with increased production of the receptor activator of the NF-kappaB ligand. |
| Q37051496 | T cells in psoriatic arthritis |
| Q34542205 | TNF ligands and receptors--a matter of life and death |
| Q35176348 | The TNF receptor superfamily: role in immune inflammation and bone formation |
| Q38332545 | The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis |
| Q41565387 | Transforming Growth Factor Beta is regulated by a Glucocorticoid-Dependent Mechanism in Denervation Mouse Bone |
| Q35592741 | Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology |
Search more.